論文明細表
科部: 內科部及癌症中心 姓名: 林璟宏
著作名稱
SCI
論文編號 ★論文必須填寫所有作者(按期刊所刊登之原排序，本
或 SSCI
*
人名下 underline)、期刊名稱（務必書寫全名）、年份、
category
月份、卷期、起迄頁數。
1
Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL.
IF
OTORHI 2.971
論文
IF 被 SCI 性質
排名 引用次 分數
刊登
雜誌
分類
及%
分數
1/44
數**
作者
排名
分數
***
得分
(CxJxA)
19
(C)
3
(J)
6
(A)
5
90
56
3
8.101
5
122
11
3
6
0.5
9
Imatinib Mesylate in the Treatment of Metastatic Adenoid Cystic NOLARY
Carcinoma. Head & Neck 2005 Dec;27(12):1022-7.
NGOLOG
2%
Y
2
Lin CH, Kuo KT, Chuang SS, Kuo SH, Chang JH, Chang KC,
Hsu HC, Tien HF, Cheng AL. Comparison of Expression and
ONCOLO 8.101 13/20
GY
3
Prognostic Significance of Differentiation Makers of Diffuse
Large B-Cell lymphoma of Central Nervous System Origin or
6%
Peripheral Nodal Origin. Clinical Cancer Research 2006
Feb;12:1152-6.
3
Kuo KT, Liang CW, Hsiao CH, Lin CH, Chen CA, Sheu BC, Lin PATHOL 5.515
5/76
MC. Downregulation of BRG-1 repressed expression of CD44s in OGY
cervical neuroendocrine carcinoma and adenocarcinoma. Mod
Pathol. 2006 Dec;19(12):1570-7.
7%
4
Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK,
PHARM
Hwang WS. A phase I study evaluating the combination of
ACOLOG
pegylated liposomal doxorubicin and paclitaxel as salvage
Y&
chemotherapy in metastatic breast cancer previously treated with
PHARM
anthracycline. CANCER CHEMOTHERAPY AND
ACY
2.560 107/2
4
3
3
3
27
38
3
6
1
18
1
3
4
0.5
6
13
3
4
0.5
6
35
3
8.958
1
27
56
42%
PHARMACOLOGY 2008 Apr;61(5):847-53.
5
Kuo KT, Hsiao CH, Lin CH, Kuo LT, Huang SH, Lin MC. The
PATHOL 5.515
biomarkers of human papillomavirus infection in tonsillar
OGY
squamous cell carcinoma-molecular basis and predicting favorable
5/76
7%
outcome. Mod Pathol. 2008 Apr;21(4):376-86.
6
Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS. OBSTET
Dose variation and regimen modification of adjuvant
RICS &
chemotherapy in daily practice affect survival of stage I-II and
GYNECO
operable stage III Taiwanese breast cancer patients. Breast 2008
LOGY
2.274 17/78
22%
Dec;17(6):646-53.
7
Huang CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin
ONCOLO 4.957 44/20
CH, Lu YS, Chang KJ. The CYP19 TTTA Repeat Polymorphism GY
3
Is Related to the Prognosis of Premenopausal Stage I–II and
Operable Stage III Breast Cancers. Oncologist 2008
22%
Jul;13(7):751-60.
8
Lin HJ, Zuo T, Lin CH, Kuo CT, Liyanarachchi S, Sun S, Shen
ONCOLO 8.958 10/20
R, Deatherage DE, Potter D, Asamoto L, Lin S, Yan PS, Cheng
GY
AL, Ostrowski MC, Huang TH. Breast cancer-associated
3
fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin
5%
M in epithelial cells. Cancer Res. 2008 Dec 15;68(24):10257-66.
9
Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen
PUBLIC,
YC, Kuo SH, Lan C, Liu J. M, Kuo WH, Chang KJ, Cheng AL.
ENVIRO
4.647 12/16
34
3
6
5
90
1
3
17.186
3
155
15
3
5
5
75
3
3
2
5
30
2
Molecular Subtypes of Breast Cancer Emerging in Young Women NMENT
in Taiwan: Evidence for More than Just Westernization as a
AL &
Reason for the Disease in Asia. CANCER EPIDEMIOLOGY
OCCUPA
BIOMARKERS & PREVENTION 2009 Jun;18(6):1807-14.
TIONAL
7%
HEALTH
10
Chang DY, Lin CH, Lu YS. Locoregional therapy improves
ONCOLO 17.186 5/203
survial for metastatic breast cancer patiets? Benefit remains
GY
questionable! JOURNAL OF CLINICAL ONCOLOGY 2009 Nov
2%
1;27(31):e179.
11
Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS, Yang CH,
RESPIRA 3.599 11/54
Wu RM, Tu YK, Tsai JC, Tseng HM, Tseng SH, Cheng AL, Lin TORY
CH*. O6-methylguanine-DNA methyltransferase expression and SYSTEM
20%
prognostic value in brain metastases of lung cancers. Lung Cancer
2010 Jun;68(3):484-90. (*corresponding author)
12
Lin CH, Lien HC, Hu FC, Lu YS, Kuo SH, Wu LC, You SL,
MEDICI
Cheng AL, Chang KJ, Huang CS. Fractionated evaluation of
NE,
immunohistochemical hormone receptor expression enhances
RESEAR
prognostic prediction in breast cancer patients treated with
CH &
tamoxifen as adjuvant therapy. Journal of Zhejiang
EXPERI
1.424 91/12
4
73%
University-SCIENCE B 2010 Jan;11(1):1-9.
13
MENTAL
Huang CS, Lin CH, Lu YS, Shen CY. Unique Features of Breast ENDOCR 3.282 33/12
Cancer in Asian Women - Breast Cancer in Taiwan as an
INOLOG
Example. JOURNAL OF STEROID BIOCHEMISTRY AND
Y&
MOLECULAR BIOLOGY 2010 Feb 28;118(4-5):300-3.
METABO
15
3
4
3
36
13
3
2
5
30
29
3
5
0.5
8
0
3
2
1
6
4
27%
LISM
14
Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, ONCOLO 2.064 152/2
Hsu C, Kuo WH, Chang KJ, Lin CH*, Cheng AL. Predictive and GY
03
Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer
Patients Treated with Paclitaxel and Cisplatin. JAPANESE
75%
JOURNAL OF CLINICAL ONCOLOGY 2010 Apr;40(4):286-93.
(*corresponding author)
15
Weng YI, Hsu PY, Liyanarachchi S, Liu J, Deatherage DE, Huang PHARM
YW, Zuo T, Rodriguez B, Lin CH, Cheng AL, Huang TH.
ACOLOG
4.163 51/25
6
Epigenetic influences of low-dose bisphenol A in primary human Y &
16
breast epithelial cells. TOXICOLOGY AND APPLIED
PHARM
PHARMACOLOGY 2010 Oct 15;248(2):111-21.
ACY
20%
Lin PH, Lu YS, Lin CH, Chang DY, Huang CS, Cheng AL, Yeh ONCOLO 1.879 145/2
KH. Vinorelbine plus 24-Hour Infusion of High-dose
GY
03
5-Fluorouracil and Leucovorin as Effective Palliative
Chemotherapy for Breast Cancer Patients with Acute
Disseminated Intravascular Coagulation. ANTICANCER
RESEARCH 2010 Jul;30(7):3087-91.
71%
17
Wang J, Shih TT, Yen RF, Lu YS, Chen CY, Mao TL, Lin CH,
RADIOL
Kuo WH, Tsai YS, Chang KJ, Chien KL. The Association of
OGY,
Infrared Imaging Findings of the Breast with Hormone Receptor
NUCLEA
2.145 46/12
3
4
0.5
6
23
3
6.002
0.5
9
10
3
5.815
0.5
9
7
3
5.617
0.5
8
2
and Human Epidermal Growth Factor Receptor 2 Status of Breast R
Cancer. ACADEMIC RADIOLOGY 2011 Feb;18(2):212-9.
5
38%
MEDICI
NE &
MEDICA
L
IMAGIN
G
18
Chen CL, Chen KC, Pan YC, Lee TP, Hsiung LC, Lin CM, Chen BIOCHE
CY, Lin CH, Chiang BL, Wo AM. Separation and detection of
8/78
MICAL
rare cells in a microfluidic disk via negative selection. LAB ON A RESEAR
CHIP 2011 Feb 7;11(3):474-83.
6.002
10%
CH
METHO
DS
19
Rodriguez BA, Weng YI, Liu TM, Zuo T, Hsu PY, Lin CH,
ONCOLO 5.815 32/20
Cheng AL, Cui H, Yan PS, Huang TH. Estrogen-Mediated
GY
3
Epigenetic Repression of the Imprinted Gene Cyclin Dependent
Kinase Inhibitor 1C in Breast Cancer Cells. Carcinogenesis 2011
16%
Jun;32(6):812-21.
20
Kuo SH, Hsu CH, Chen LT, Lu YS, Lin CH, Yeh PY, Jeng HJ,
ONCOLO 5.617 41/20
Gao M, Yeh KH, Cheng AL. Lack of compensatory pAKT
GY
3
activation and eIF4E phosphorylation of lymphoma cells towards
mTOR inhibitor, RAD001. EUROPEAN JOURNAL OF
20%
CANCER 2011 May;47(8):1244-57.
21
Hsiung LC, Chiang CL, Wang CH, Huang YH, Kuo CT, Cheng
BIOCHE
JY, Lin CH, Wu V, Chou HY, Jong DS, Lee H, Wo AM.
MICAL
Dielectrophoresis-based cellular microarray chip for anticancer
RESEAR
drug screening in perfusion microenvironments. Lab Chip. 2011
CH
Jul 21;11(14):2333–42.
METHO
6.002
8/78
19
3
6.002
0.5
9
3
3
29.914
3
269
4
3
4
5
60
6
3
4
3
36
10%
DS
22
Chen IC, Lin CH, Lu YS. Axillary vs Sentinel Lymph Node
MEDICI
Dissection for Invasive Breast Cancer. JAMA-JOURNAL OF
NE,
THE AMERICAN MEDICAL ASSOCIATION 2011 Jun
GENERA
8;305(22):2288-9.
L&
29.914 3/156
2%
INTERN
AL
23
Lin CH, Lu YS, Huang CS, Kuo KT, Wang CC, You SL, Lin PH, PATHOL
Chang DW, Kuo WH, Chang KJ, Cheng AL. Prognostic
OGY
molecular markers in women aged 35 years or younger with breast
cancer– Is there a difference from the older patients? JOURNAL
2.529 25/76
33%
OF CLINICAL PATHOLOGY 2011 Sep;64(9):781-7.
24
Chen IC, Lin CH, Huang CS, Lien HC, HsuC, Kuo WH, Lu YS, ONCOLO 4.274 49/20
Cheng AL. Lack of efficacy to systemic chemotherapy for GY
3
treatment of metaplastic carcinoma of the breast in the modern
era. BREAST CANCER RESEARCH AND TREATMENT 2011
24%
Nov;130(1):345-51.
25
26
Kuo WH, Lin PH, Huang AC, Chien YH, Liu TP, Lu YS, Bai LY, GENETI
Sargeant AM, Lin CH, Cheng AL, Hsieh FJ, Hwu WL, Chang CS &
KJ. Multimodel assessment of BRCA1 mutations in Taiwanese HEREDI
(ethnic Chinese) women with early-onset, bilateral or familial TY
breast cancer. JOURNAL OF HUMAN GENETICS 2012
Feb;57(2):130-8.
Lin YC, Chen KC, Lin CH, Kuo KT, Ko JY, Hong RL.
Clinicopathological features of salivary and non-salivary adenoid
cystic carcinomas. INTERNATIONAL JOURNAL OF ORAL
AND MAXILLOFACIAL SURGERY 2012 Mar;41(3):354-60.
2.411 87/16
1
3
3
0.5
5
6
3
3
1
9
10
3
5.497
5
82
2
3
3
0.5
5
0
3
17.186
1
52
5
53%
DENTIST 1.788 36/83
RY,
ORAL
43%
SURGER
Y&
MEDICI
NE
27
ONCOLO 5.497 34/20
Lin CH, Chen YC, Chiang CL, Lu YS, Kuo KT, Huang CS,
Cheng WF, Lai MS, You SL, Cheng AL. The emerging epidemic GY
3
of estrogen-related cancers in young women in a developing Asian
country. INTERNATIONAL JOURNAL OF CANCER 2012 Jun
17%
1;130(11):2629-37.
28
Chen KC, Pan YC, Chen CL, Lin CH, Huang CS, Wo AM.
Enumeration and viability of rare cells in a microfluidic disk via
positive selection approach. ANALYTICAL BIOCHEMISTRY
2012 Oct 15;429(2):116-23.
29
CHEMIS
2.749 32/76
TRY,
ANALYT
42%
ICAL
Liang YH, Wu PF, Lin CH, Lu YS. Hashimoto's Encephalopathy ONCOLO 17.186 5/203
As the Cause of Deteriorating Consciousness During Treatment of GY
Leptomeningeal Carcinomatosis From Breast Cancer. J Clin
Oncol. 2012 Nov 20;30(33):e358-9.
2%
30
Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu ONCOLO 3.640 74/20
C, Lu YS, Cheng AL. Dynamics of circulating endothelial cells
GY
3
and endothelial progenitor cells in breast cancer patients receiving
cytotoxic chemotherapy. BMC Cancer 2012 Dec 26;12(1):620.
36%
0
3
4
3
36
31
PATHOL
Lin CH, Liu JM, Lu YS, Lan C, Lee WC, Kuo KT, Wang CC,
Chang DY, Huang CS, Cheng AL. Clinical significance of ESR1 OGY
gene copy number changes in breast cancer as measured by
fluorescence in situ hybridisation. J Clin Pathol. 2013
Feb;66(2):140-5.
3
3
4
5
60
11
3
2
0.5
3
1
3
4
1
12
3
3
3
5
45
32
33
2.529 25/76
33%
Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, Li H, ONCOLO 1.467 157/2
Lin YC, Chang HK, Chao TC, Ouyang F, Hou MF. Distant
metastasis in triple-negative breast cancer. Neoplasma
2013;60(3):290-4.
GY
Lien HC, Wang CC, Lin CH, Lu YS, Huang CS, Hsiao LP, Yao
YT. Differential expression of ubiquitin carboxy-terminal
hydrolase L1 in breast carcinoma and its biological significance.
PATHOL
03
77%
3.024 21/76
OGY
28%
HUMAN PATHOLOGY 2013 Sep;44(9):1838-48.
34
Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH*, ONCOLO 2.950 97/20
Cheng AL. Phosphorylated insulin-like growth factor-1 receptor
GY
3
(pIGF1R) is a poor prognostic factor in brain metastases from
lung adenocarcinomas. J Neurooncol. 2013 Oct;115(1):61-70.
48%
(*corresponding author)
35
36
Chen WW, Chang DY, Huang SM, Lin CH, Hsu C, Lin MH,
Huang CS, Lu YS, Cheng AL. The first two lines of
chemotherapy for anthracycline-naive metastatic breast cancer: A
comparative study of the efficacy of anthracyclines and
non-anthracyclines. Breast 2013 Dec;22(6):1148-54.
OBSTET
Kuo SH, Yang SY, Lien HC, Lo C, Lin CH, Lu YS, Cheng AL,
NA
2.274 17/78
0
3
4
0.5
6
0
3
NA
0.5
NA
2
3
4
0.5
6
1
3
4
5
60
1
3
6
0.5
9
RICS &
GYNECO
22%
LOGY
NA
NA
Chang KJ, Huang CS. CYP19 genetic polymorphism haplotype
AASA is associated with a poor prognosis in premenopausal
women with lymph node-negative, hormone receptor-positive
breast cancer. Biomed Research International 2013; 2013:562197.
37
Lien HC, Lee YH, Jeng YM, Lin CH, Lu YS, Yao YT.
Differential expression of hyaluronan synthase 2 in breast
carcinoma and its biological significance. Histopathology 2014
PATHOL
3.607 16/76
OGY
21%
Sep;65(3):328-39.
38
Lin CH, Chuang PY, Chiang CL, Lu YS, Cheng AL, Kuo WH, ONCOLO 4.957 44/20
Huang CS, Lai MS, You SL, Tang CH. Distinct
GY
3
Clinicopathological Features and Prognosis of Emerging Young
Female Breast Cancer in an East Asian Country: a Nationwide
22%
Cancer Registry-based Study. Oncologist 2014 Jun;19(6):583-91.
39
Liao HW, Tsai IL, Chen GY, Lu YS, Lin CH, Kuo CH.
Quantification of target analytes in various biofluids using a
postcolumn infused-internal standard method combined with
matrix normalization factors in liquid
chromatography-electrospray ionization mass spectrometry.
CHEMIS
4.339
6/76
TRY,
ANALYT
ICAL
8%
JOURNAL OF CHROMATOGRAPHY A 2014 Jun 30. pii:
S0021-9673(14)01012-7; 2014 Sep 5;1358:85-92.
40
41
Kuo CT, Liu HK, Huang GS, Chang CH, Chen CL, Chen KC,
Yun-Ju Huang R, Lin CH, Lee H, Huang CS, Wo AM. A
spatiotemporally defined in vitro microenvironment for
controllable signal delivery and drug screening. Analyst 2014 Aug
4. [Epub ahead of print]; 139(19):4846-54.
CHEMIS
4.097
7/76
0
3
6
0.5
9
0
3
4
1
12
TRY,
ANALYT
9%
ICAL
PATHOL
Huang HN, Huang WC, Lin CH, Chiang YC, Huang HY, Kuo
KT. Chromosome 20q13.2 ZNF217 locus amplification correlates OGY
with decreased E-cadherin expression in ovarian clear cell
carcinoma with PI3K-Akt pathway alterations. Hum Pathol. 2014
Nov;45(11):2318-25.
3.024 21/76
28%
42
Chen TW, Chen HM, Lin CH, Huang CS, Cheng AL, Lai MS, Lu ONCOLO 4.274 49/20
YS. No increased venous thromboembolism risk in Asian breast GY
3
cancer patients receiving adjuvant tamoxifen. Breast Cancer Res
Treat. 2014 Nov;148(1):135-42.
24%
0
3
4
1
12
43
ONCOLO 8.101 13/20
Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau
KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng
GY
3
AL. Bevacizumab Preconditioning Followed by Etoposide and
Cisplatin Is Highly Effective in Treating Brain Metastases of
6%
Breast Cancer Progressing from Whole-Brain Radiotherapy. Clin
Cancer Res. 2015 Feb 19. pii: clincanres.2075.2014. [Epub ahead
of print]
0
3
8.101
1
24
44
Ma WY, Hsiung LC, Wang CH, Chiang CL, Lin CH, Huang CS, MULTIDI 5.078
Wo AM. A Novel 96well-formatted Micro-gap Plate Enabling
SCIPLIN
0
3
6
0.5
9
5/55
Drug Response Profiling on Primary Tumour Samples. Scientific ARY
Reports 2015 [Epub ahead of print]
9%
SCIENCE
S
45
MULTIDI 4.015
Lin CH, Shen CY, Lee JH, Huang CS, Yang CH, Kuo WH,
Chang DW, Hsiung CN, Kuo KT, Chen WW, Chen IC, Wu PF, SCIPLIN
Kuo SH, Chen CJ, Lu YS, Cheng AL. High Prevalence of the BIM ARY
Deletion Polymorphism in Young Female Breast Cancer in an
SCIENCE
East Asian Country. Plos One 2015 [Epub ahead of print]
46
總
Chang C, Lin CH, Cheng AL, Chang KC. Primary Central
Nervous System Diffuse Large B-cell Lymphoma Has Poorer
Immune Cell Infiltration and Prognosis than Peripheral
Counterpart. Histopathology 2015 [Epub ahead of print]
分****
8/55
0
3
5
5
75
0
3
4
3
36
15%
S
PATHOL
3.607 16/76
OGY
21%
1708